1139 related articles for article (PubMed ID: 26313362)
1. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
[TBL] [Abstract][Full Text] [Related]
2. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA
Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.
Ikeda S; Okamoto T; Okano S; Umemoto Y; Tagawa T; Morodomi Y; Kohno M; Shimamatsu S; Kitahara H; Suzuki Y; Fujishita T; Maehara Y
J Thorac Oncol; 2016 Jan; 11(1):62-71. PubMed ID: 26762740
[TBL] [Abstract][Full Text] [Related]
6. Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer.
Igawa S; Sato Y; Ryuge S; Ichinoe M; Katono K; Hiyoshi Y; Otani S; Nagashio R; Nakashima H; Katagiri M; Sasaki J; Murakumo Y; Satoh Y; Masuda N
Oncology; 2017; 92(5):283-290. PubMed ID: 28222447
[TBL] [Abstract][Full Text] [Related]
7. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological significance of KAI1 expression and epithelial-mesenchymal transition in non-small cell lung cancer.
Zhou L; Yu L; Wu S; Feng Z; Song W; Gong X
World J Surg Oncol; 2015 Aug; 13():234. PubMed ID: 26231404
[TBL] [Abstract][Full Text] [Related]
9. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).
Grossi F; Spizzo R; Bordo D; Cacitti V; Valent F; Rossetto C; Follador A; Di Terlizzi S; Aita M; Morelli A; Fasola G; Consiglieri C; Ceschia T; Beltrami CA; Belvedere O
J Thorac Oncol; 2010 Sep; 5(9):1354-60. PubMed ID: 20631638
[TBL] [Abstract][Full Text] [Related]
10. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.
Sacher AG; Gandhi L
JAMA Oncol; 2016 Sep; 2(9):1217-22. PubMed ID: 27310809
[TBL] [Abstract][Full Text] [Related]
12. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
[TBL] [Abstract][Full Text] [Related]
14. Ly6/uPAR-related protein C4.4A as a marker of solid growth pattern and poor prognosis in lung adenocarcinoma.
Jacobsen B; Muley T; Meister M; Dienemann H; Christensen IJ; Santoni-Rugiu E; Lærum OD; Ploug M
J Thorac Oncol; 2013 Feb; 8(2):152-60. PubMed ID: 23287851
[TBL] [Abstract][Full Text] [Related]
15. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer.
Otsuka S; Klimowicz AC; Kopciuk K; Petrillo SK; Konno M; Hao D; Muzik H; Stolte E; Boland W; Morris D; Magliocco AM; Bebb DG
J Thorac Oncol; 2011 Jul; 6(7):1169-78. PubMed ID: 21623238
[TBL] [Abstract][Full Text] [Related]
16. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
[TBL] [Abstract][Full Text] [Related]
17. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
Takada K; Okamoto T; Toyokawa G; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological significance of the expression of PD-L1 in non-small cell lung cancer.
Montero MA; Aricak O; Kis L; Yoshikawa A; De Petris L; Grundberg O; Pham HHN; Roden AC; Fukuoka J; Attanoos R; Guijarro R; Alarcón F; Lindström K; Ortiz-Villalón C
Ann Diagn Pathol; 2021 Apr; 51():151701. PubMed ID: 33485052
[TBL] [Abstract][Full Text] [Related]
19. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer.
Ishii H; Azuma K; Kawahara A; Yamada K; Imamura Y; Tokito T; Kinoshita T; Kage M; Hoshino T
J Thorac Oncol; 2015 Mar; 10(3):426-30. PubMed ID: 25384063
[TBL] [Abstract][Full Text] [Related]
20. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
